ADX#

Related by string. * * Study ADX# *

Related by context. All words. (Click for frequent words.) 69 dyskinesia PD LID 68 mGluR5 negative 67 mGluR2 positive 66 Parkinson disease levodopa induced 66 NGX# 65 allosteric modulator NAM 65 Phase IIa trial 65 Dapagliflozin 64 Traficet EN 64 Mipomersen 64 ISIS # 64 Phase 2a trial 64 tezampanel 63 cannabinor 63 MAP# 63 Phase IIa 63 Phase 2b study 63 mGluR5 NAM 63 oral prodrug 63 RDEA# 63 Pimavanserin 63 PD LID 62 PRX # 62 teriflunomide 62 administered subcutaneously 62 adipiplon 62 JAK inhibitor 62 aripiprazole Abilify 62 selective modulator 62 Phase 2a 62 phase IIa clinical 62 ProSavin 61 peripherally acting 61 alvimopan 61 Phase 2b clinical 61 INCB# [001] 61 oral rivaroxaban 61 BCX# 61 Phase IIb trials 61 eprotirome 61 INCB# [002] 61 SCH # 61 BAY #-# 61 Phase 2a clinical 61 LEVADEX 61 ganetespib 61 PSN# [002] 61 palonosetron 61 nitazoxanide 61 allosteric modulator 61 Phase Ib 60 investigational drug 60 LY# [002] 60 Capesaris 60 preclinical studies 60 Phase IIa clinical 60 phase IIa 60 Locteron 60 Corlux 60 PDE4 inhibitor 60 forodesine 60 KRN# 60 QLT# 60 SILENOR TM 60 RSD# 60 HuMax CD4 60 vidofludimus 60 inhaled formulation 60 Rivaroxaban 60 PRT# 60 Dasatinib 60 MGCD# [001] 60 phase IIb clinical 60 pseudobulbar affect PBA 60 receptor antagonists 60 safinamide 60 Gabapentin GR 60 bifeprunox 60 rNAPc2 60 PS# [001] 60 zileuton 60 opioid induced bowel dysfunction 60 DDP# 60 orally administered 60 Serdaxin 60 IDX# 60 Phase 2b 60 Phase IIb 60 NKTR 60 LY# [003] 59 phase 2a 59 receptor antagonist 59 aripiprazole 59 Safinamide 59 Panzem R 59 elotuzumab 59 CORLUX 59 investigational compound 59 coadministration 59 tanespimycin 59 placebo controlled clinical 59 6R BH4 59 GAMMAGARD 59 sorafenib Nexavar 59 PEG Interferon lambda 59 PRISTIQ 59 phase IIb 59 telcagepant 59 teduglutide 59 GLYX 59 integrase inhibitor 59 INT# [002] 59 SRT# [003] 59 MEK inhibitor 59 atacicept 59 Locteron ® 59 visilizumab 59 metaglidasen 59 reslizumab 59 5 HT3 receptor 59 VA# [002] 59 desvenlafaxine succinate 59 YONDELIS 59 tolerability profile 59 intranasal formulation 59 allosteric modulator PAM 59 CORT # 59 JANUVIA 59 Nexavar ® 59 selective androgen receptor modulator 59 investigational humanized monoclonal antibody 59 interferon beta 1b 59 methylnaltrexone 59 AEGR 59 canakinumab 59 Phase III clinical 59 HCV protease inhibitor 59 TriRima 59 IRX 2 59 PEGPH# 59 Boceprevir 59 ICA # 59 lomitapide 59 huC# DM4 59 diabetic neuropathic pain 59 subcutaneously administered 59 Cleviprex TM clevidipine 59 Plicera 59 Archexin 59 cediranib 59 Bezielle 59 antiplatelet agent 59 Preclinical studies suggest 59 EOquin 59 Fx #A 59 proteasome inhibitor 59 PF # [001] 59 Phenoptin 59 Androxal TM 59 OncoVEX GM CSF 59 PEG SN# 59 LIVALO 59 NVA# 59 XmAb# 59 CB2 selective receptor agonist 58 virus HCV protease inhibitor 58 Tezampanel 58 Bicifadine 58 albiglutide 58 SNRI 58 mertansine 58 zolmitriptan 58 eniluracil 58 multiple ascending dose 58 QNEXA 58 avanafil 58 PBT2 58 oral formulation 58 HuMax CD# 58 GALNS 58 Amrubicin 58 Rezular 58 angiogenesis inhibitor 58 desvenlafaxine 58 elagolix 58 pharmacodynamic 58 active comparator 58 partial agonist 58 TRIOLEX 58 RG# [001] 58 Naproxcinod 58 Golimumab 58 Ocrelizumab 58 LT NS# 58 mg dose 58 R#/MEM # 58 pramlintide 58 TBC# 58 Vicriviroc 58 preclinical 58 Oral NKTR 58 TELINTRA 58 Menerba 58 Zerenex 58 ancrod 58 Tolvaptan 58 PHX# 58 Phase 1b 58 glatiramer acetate 58 posaconazole 58 sitagliptin 58 bicifadine 58 Phase 1a clinical 58 LymphoStat B 58 Carfilzomib 58 AGILECT R 58 AZILECT R 58 Microplasmin 58 lurasidone 58 fluticasone furoate 58 Phase Ib study 58 Laquinimod 58 non nucleoside inhibitor 58 CRx 58 Phase IIa trials 58 HFA MDI 58 Lu AA# 58 midstage clinical 58 RhuDex ® 58 CBLC# 58 QNEXA ® 58 Aptivus ® 58 diarrhea predominant irritable 58 acyclovir Lauriad R 58 CG# [003] 58 mTOR inhibitor 58 HuLuc# 58 Levadex 58 HuMax EGFr 58 PEGylated anti 58 Cannabinor 58 GSK# [002] 58 uric acid lowering 58 pegylated interferons 58 Pertuzumab 58 BNC# 58 PNP inhibitor 58 Phase 2b clinical trials 58 Phase IIb trial 58 torezolid phosphate 58 tolerability 58 CEQ# 58 refractory gout 58 Aflibercept 58 CIMZIA ™ 58 ocrelizumab 58 laquinimod 57 MNTX 57 tocilizumab 57 IND enabling 57 orally dosed 57 alvespimycin 57 CCR5 antagonist 57 oral FTY# 57 ADVANCE PD 57 Phase 2a clinical trials 57 riociguat 57 Darusentan 57 Onalta 57 LEVADEX TM 57 Tyrima 57 FTY# 57 DG# [001] 57 Xanafide 57 CDP# 57 Phase IIb Trial 57 injectable formulation 57 mipomersen 57 Fibrillex TM 57 selective agonist 57 Excellarate 57 adalimumab Humira 57 CCX# 57 aliskiren 57 Ostarine 57 compound INCB# 57 bosentan 57 Debio 57 Vaprisol 57 tasocitinib 57 AEZS 57 long acting muscarinic 57 AEG# 57 CIMZIA TM 57 Phase Ib clinical 57 Cethromycin 57 Civacir 57 PCK# 57 otelixizumab 57 DB# [003] 57 entinostat 57 SPC# [001] 57 Phase III clinical trials 57 Phase IIb clinical 57 epothilone 57 Aerosurf 57 Pivotal Phase 57 biologic therapy 57 Tasimelteon 57 baminercept 57 FASLODEX 57 TPI ASM8 57 mu opioid receptor antagonist 57 placebo controlled Phase 57 RGB # 57 ramelteon 57 vascular disrupting agent 57 dirucotide 57 Tanespimycin 57 Aliskiren 57 APTIVUS 57 ibudilast 57 Zenvia 57 tecarfarin 57 telbivudine 57 Phase III trials 57 class mGluR5 inhibitor 57 Phase 2b trial 57 Phase 2a Clinical Trial 57 GFT# 57 insulin sensitizers 57 perampanel 57 GAMMAGARD LIQUID 57 PDE4 inhibitors 57 endothelin receptor antagonists 57 Lixivaptan 57 APTIVUS r 57 febuxostat 57 nebulized formoterol fumarate 57 cathepsin K inhibitor 57 Ophena TM 57 sitaxsentan 57 rilonacept 57 beta 1a 57 ALKS 57 AQ4N 57 anticancer agent 57 APEX PD 57 orally administered inhibitor 57 eltrombopag 57 metabotropic glutamate receptor 57 fostamatinib 57 ACTEMRA TM 57 TACI Ig 57 Lixisenatide 57 angiotensin receptor blocker ARB 57 intravenous formulation 57 Adalimumab 57 dacetuzumab 57 Chemophase 57 mGluR2 NAM 57 cangrelor 57 nalbuphine ER 57 renin inhibitor 57 eszopiclone 57 LAF# 57 vilazodone 57 Pazopanib 57 docetaxel Taxotere ® 57 polymerase inhibitor 57 Synavive 57 humanized anti 57 Milnacipran 57 MLN# 57 Icatibant 57 Alfimeprase 57 Avanafil 57 Trexima 57 BAL# [002] 57 TRO# 57 Dyloject TM 57 generation purine nucleoside 57 monotherapy 57 Methylnaltrexone 57 temsirolimus 57 Apoptone 57 SERMs 56 Adlea 56 Genz # 56 ENBREL 56 HQK 56 intravenous dosing 56 Phase Ib clinical trials 56 Phase 1b trial 56 ORENCIA R 56 synthetic retinoid 56 aprepitant 56 APF# 56 Epanova 56 systemically administered 56 TELCYTA 56 olanzapine Zyprexa 56 ARRY 56 pharmacokinetic 56 histone deacetylase HDAC inhibitor 56 CoFactor 56 Valdoxan 56 Vilazodone 56 oral methylnaltrexone 56 CTAP# Capsules 56 TRX1 56 MBP# [001] 56 SPRYCEL 56 phase IIb trial 56 daclizumab 56 ALN PCS 56 SinuNase TM 56 Factor VIIa 56 SGS# 56 receptor tyrosine kinase inhibitor 56 Phase #b/#a trial 56 Arcalyst 56 albinterferon alfa 2b 56 ALN TTR# 56 DAPT 56 pertuzumab 56 ularitide 56 CDK inhibitor 56 phase Ib 56 Interferon alpha 56 NOXAFIL 56 Linagliptin 56 receptor agonists 56 Ixabepilone 56 PXD# 56 MB# [004] 56 PRTX 56 MEK inhibitors 56 RAPAFLO 56 ZD# [001] 56 asenapine 56 Clonicel 56 ALGRX 56 orally bioavailable 56 DU #b 56 Ozarelix 56 OvaRex ® MAb 56 Cimzia ® 56 anti amnesic 56 QVA# 56 subcutaneous formulation 56 ANG# 56 Triolex 56 ANAVEX #-# [003] 56 liposomal formulation 56 Voreloxin 56 sorafenib tablets 56 Relovair 56 nucleoside analog 56 Q#IR 56 tiotropium bromide 56 GSK# [001] 56 ISENTRESS 56 disease modifying 56 GHRH 56 trospium 56 ORENCIA ® 56 OMNARIS HFA 56 deforolimus 56 TNF Tumor Necrosis Factor 56 VAPRISOL 56 KNS # 56 Ambrisentan 56 prodrug 56 risperidone Risperdal 56 paliperidone palmitate 56 infliximab Remicade 56 oral proteasome inhibitor 56 investigational oral 56 EXPAREL ™ 56 pitavastatin 56 ATL# [001] 56 lacosamide 56 Frova ® 56 Clevudine 56 targeted radiotherapeutic 56 Vidofludimus 56 almorexant 56 HCD# [002] 56 Durezol 56 brivaracetam 56 PEGylated Fab fragment 56 SNT MC# 56 LibiGel ® 56 Bortezomib 56 Technosphere Insulin 56 rHuPH# 56 TNF inhibitor 56 Tamibarotene 56 ulimorelin 56 Nasulin 56 Guanilib 56 Phase 1a 56 tigecycline 56 dosing cohorts 56 ruxolitinib 56 modulators SERMs 56 TMC# [002] 56 Protexia ® 56 IPX# 56 Dacogen injection 56 Dalbavancin 56 relapsed multiple myeloma 56 dexpramipexole 56 Trastuzumab 56 pharmacokinetic studies 56 CR# vcMMAE 56 oral antiviral 56 ELND# 56 LEXIVA 56 Elagolix 56 ocular formulation 56 pramipexole 56 #mg dose [001] 56 Prodarsan ® 56 methylnaltrexone bromide 56 EGS# 56 Huntexil 56 Phase 2b Clinical Trial 56 evaluating tivozanib 56 novel VDA molecule 56 opioid bowel dysfunction 56 TREANDA 56 Lisofylline LSF 56 pan HDAC inhibitor 56 GLPG# 56 dimebon 56 calcitonin 56 ACTEMRA 56 E2F Decoy 56 dose escalation trial 56 davalintide 56 oral anticoagulant 56 DAVANAT 56 Iloperidone 56 rotigotine 55 Alzhemed TM 55 fosbretabulin 55 Hsp# inhibitor 55 active moiety 55 Sym# 55 5 HT2A receptor 55 pivotal Phase III 55 oral dosing 55 delta opioid receptor 55 GRN#L 55 MoxDuo TM IR 55 Phase 1b clinical 55 edoxaban 55 Bosutinib 55 Zoraxel 55 Azixa 55 subcutaneous SC 55 Phase Ia 55 rFIXFc 55 anticancer compound 55 prucalopride 55 secondary efficacy endpoints 55 fenretinide 55 candidate Zenvia 55 TRV# [001] 55 proteasome inhibitors 55 muraglitazar 55 Anavex #-# 55 oral ridaforolimus 55 rindopepimut 55 AMITIZA 55 trodusquemine 55 AAG geldanamycin analog 55 mGluR5 inhibitors 55 confirmatory Phase III 55 lumiliximab 55 MoxDuo IR 55 Tiotropium 55 alagebrium 55 Phase IIIb 55 glucagon receptor 55 TREDAPTIVE 55 esomeprazole 55 Radezolid 55 icatibant 55 Silodosin 55 FM VP4 55 octreotide 55 elacytarabine 55 Linaclotide 55 Omacetaxine mepesuccinate 55 Liraglutide 55 bardoxolone methyl 55 Targretin 55 triphendiol 55 ALV# 55 Phase III Clinical Trial 55 Sitagliptin 55 modulator SERM 55 Staccato loxapine 55 tasimelteon 55 Phase IIB 55 ARIKACE 55 hypercholesterolemia 55 Cimzia certolizumab pegol 55 Meets Primary Endpoint 55 Maribavir 55 Phase IIIb clinical 55 IMA# 55 ONGLYZA 55 BRIM2 55 vicriviroc 55 investigational monoclonal antibody 55 Rebif ® 55 Exherin TM 55 CorVue ™ 55 TYGACIL 55 HGS# 55 SEROQUEL 55 sulodexide 55 AZD# 55 mg QD 55 tiapamil 55 photoprotective drug 55 ALTU 55 SUPPRELIN R LA 55 atypical antipsychotic 55 RezularTM 55 XOPENEX HFA 55 CYT# 55 Eltrombopag 55 citalopram 55 lucinactant 55 GATTEX 55 LCP Tacro 55 LCP AtorFen 55 PEG PAL 55 Perifosine 55 ritonavir boosted 55 pradefovir 55 insulin sensitizing 55 Inhalation Solution 55 #ME# 55 KB# [002] 55 Omacetaxine 55 Pegasys ® 55 AeroLEF TM 55 2 methoxyestradiol 55 SPP# [001] 55 Serdaxin ® 55 R#/MEM 55 Initiate Phase 55 pharmacokinetic pharmacodynamic 55 MT# MEDI 55 insulin sensitizer 55 pharmacokinetics PK 55 tezampanel NGX# 55 RoACTEMRA 55 Rotigotine 55 IAP inhibitors 55 Saxagliptin 55 casopitant 55 Ophena 55 dextofisopam 55 budesonide 55 lixisenatide 55 Ventavis 55 pharmacokinetic PK 55 dimebon latrepirdine 55 SILENOR 55 Tocilizumab 55 Symadex 55 IND submission 55 MKC# MKC# PP 55 PREOS 55 Combo Stent 55 vorinostat 55 TOCOSOL Paclitaxel 55 preclinically 55 HCV SPRINT 55 selective estrogen receptor 55 TMC# C# 55 Initiated Phase 55 Afatinib 55 CYT# potent vascular disrupting 55 Daclizumab 55 investigational protease inhibitor 55 signal transduction inhibitor 55 APD# 55 sodium glucose cotransporter 55 somatostatin analogue 55 guanfacine 55 inhibitor RG# 55 Ecallantide 55 CD# CEA 55 senicapoc 55 edifoligide 55 ULORIC 55 Losartan 55 certolizumab pegol 55 xanthine oxidase inhibitor 55 APPRAISE 55 DermaVir Patch 55 Lodotra TM 55 highly selective inhibitor 55 GGF2 55 investigational pan BCR 55 ATL/TV# 55 AVE# 55 preclinical efficacy 55 zonisamide SR 55 ixabepilone 55 dosing frequency 55 carfilzomib 55 catheter occlusion 55 lubiprostone 55 SYMBICORT 55 RhuDex 55 receptor inhibitor 55 radezolid 55 Sprycel dasatinib 55 Tesetaxel 55 Lubiprostone 55 serotonin norepinephrine reuptake inhibitor 55 mGluR5 inhibition 55 valsartan 55 HCV protease 55 REG1 55 adefovir 55 velafermin 55 MERLIN TIMI 55 TLR9 agonist 55 perifosine 55 #D#C# 55 pharmacokinetic profile 55 Excellarate TM 55 XL# [003] 54 ospemifene 54 proton pump inhibitor PPI 54 ALN TTR 54 TKM ApoB 54 cilengitide 54 bexarotene 54 Multaq R 54 Onconase 54 oral Xeloda 54 NRTI 54 enoximone 54 lamotrigine 54 pomalidomide 54 HIV integrase inhibitor 54 ATryn R 54 XP# XP# 54 seliciclib CYC# 54 LymphoStat B belimumab 54 amrubicin 54 ALVESCO R 54 Aclidinium 54 tolvaptan 54 oxymorphone ER 54 DFMO 54 teriparatide 54 Atrasentan 54 TLK# 54 Panzem R NCD 54 Diamyd ® 54 BEMA TM Fentanyl 54 atrasentan 54 Pivotal Phase III 54 Alinia 54 LEVADEX ™ 54 obatoclax 54 tolerability profiles 54 CD# antibody [001] 54 enzastaurin 54 TAFA# 54 PKC# 54 NUVIGIL 54 Ketotransdel 54 MIRCERA 54 Amigal 54 inhaled corticosteroid ICS 54 Nanobody ® 54 Aurora kinase inhibitor 54 DR Cysteamine 54 Hsp# Inhibitor 54 preclinical toxicology 54 dosing regimens 54 IIIa inhibitor 54 EOquin TM 54 Denufosol 54 tafamidis 54 OXi# 54 decitabine 54 Perforomist TM Inhalation Solution 54 Indaflex TM 54 DXL# 54 Elvitegravir 54 dasatinib 54 CANCIDAS 54 humanized monoclonal antibody 54 TYZEKA 54 goserelin 54 ibandronate 54 panitumumab Vectibix 54 zafirlukast 54 gamma secretase inhibitor 54 guanfacine extended release 54 Tarceva TM 54 Cetrorelix 54 Altastaph 54 Muraglitazar 54 Pharmacokinetic 54 alemtuzumab Campath 54 Gattex 54 VEGF Trap 54 Protelos 54 Randomized Phase 54 Anthim 54 NP2 Enkephalin 54 mecamylamine 54 eculizumab 54 Phase IIa proof 54 Androxal 54 potent inhibitor 54 MAXY G# 54 darusentan 54 abatacept 54 SARMs 54 LHRH antagonist 54 Personalized Immunotherapy 54 Starlix 54 ZOLINZA 54 Fc fusion protein 54 PLK1 SNALP 54 CA4P 54 TOLAMBA 54 muscarinic 54 Azilect ® 54 pharmacodynamic properties 54 olaparib 54 generation antisense 54 pharmacodynamic PD 54 intravenously administered 54 Phase IIb clinical trials 54 Zoloft sertraline 54 pharmacological chaperone 54 BARACLUDE R 54 sodium Injection 54 immunomodulator 54 tenofovir Viread 54 Monotherapy 54 Marqibo 54 pregabalin Lyrica 54 ascending dose 54 TH# [003] 54 maximally tolerated dose 54 polymerase inhibitors 54 eosinophilic asthma 54 Phase III 54 nab paclitaxel 54 Firazyr 54 calcineurin inhibitors 54 anti leukemic 54 Fulvestrant 54 Chrysalin 54 lanthanum carbonate 54 DPP4 inhibitor 54 HCV NS5B polymerase 54 #mg doses [002] 54 lixivaptan 54 Emselex 54 GATTEX TM 54 multicenter Phase 54 trial evaluating PRX# 54 Phase III placebo controlled 54 Genasense R oblimersen 54 motexafin gadolinium Injection 54 Glatiramer Acetate 54 ACE inhibitor ramipril 54 Mg Uk 54 Phase #/#a 54 PRE SURGE 54 blinatumomab 54 MoxDuo 54 receptor partial agonist 54 selective antagonist 54 migraine prophylaxis 54 Perforomist ™ Inhalation Solution 54 relapsed myeloma 54 salmeterol fluticasone 54 Thiarabine 54 antisense drug 54 COPAXONE R 54 DASISION 54 SUTENT ® 54 PEGINTRON TM 54 Candesartan 54 RLY# 54 herpetic keratitis 54 Acetavance 54 SCIg 54 oral bioavailability 54 azilsartan medoxomil 54 lapatinib Tykerb 54 Enhanze Technology 54 Everolimus 54 Posiphen 54 erlotinib Tarceva ® 54 ozarelix 54 novel nucleoside analog 54 varespladib 54 interferon alfa 54 Phase IIa clinical trials 54 partial agonists 54 prescribed proton pump 54 EndoTAG TM -1 54 IMGN# 54 MEK inhibitor RDEA# 54 CINOD 54 Unit Dose Budesonide 54 PEG INTRON 54 Onbrez Breezhaler 54 AVONEX ® 54 LEP ETU 54 adalimumab 54 tyrosine kinase inhibitor 54 LE SN# 54 APOPTONE 54 Ranolazine 54 Alvesco R 54 Investigational Compound 54 functional dyspepsia 54 PROMACTA 54 Indiplon 54 ADL# 54 GOUT 54 lorvotuzumab mertansine 54 bosutinib 54 Eculizumab 54 LPA1 receptor 54 phase IIb study 54 tanezumab 54 Phase 2b Trial 54 Amplimexon 54 antibody MAb 54 PREZISTA r 54 DP b# 54 valproate 54 CD3 monoclonal antibody 54 Syncria 54 ONCONASE R 54 etanercept Enbrel 54 nucleotide analog 54 dexamethasone Decadron 54 viral kinetic 54 HZT 54 interferon beta 54 Hyphanox 54 VQD 54 ONCONASE 54 Uricase PEG 54 HGS ETR1 54 ALN VSP 54 Zenvia Phase III 54 ongoing Phase 1b 54 volociximab 54 microplasmin 54 insulin degludec 54 M6G 54 AVN# [001] 54 ThGRF 54 ARCOXIA 54 sulindac 54 generation antisense inhibitor 54 betrixaban 54 ATL# [002] 54 molecular imaging radiopharmaceutical 54 liprotamase 54 receptor agonist 54 corticosteroid dexamethasone 54 SAR# [004] 54 Raptiva ® 54 olmesartan 54 Cimzia TM 54 Torisel 54 Valsartan 54 placebo controlled 54 YONDELIS R 54 axitinib 54 Blinatumomab 53 Omnitarg 53 ILUVIEN ®

Back to home page